Multiple Myeloma, Refractory Clinical Trials

47 clinical trials for Multiple Myeloma, Refractory across international registries, including 20 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE2
• Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager — RECRUITING · PHASE4
• Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) — RECRUITING · PHASE1
• CAR-T in Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma — RECRUITING · PHASE1
• HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM — RECRUITING · PHASE2
• Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma — RECRUITING · PHASE1
• A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. — RECRUITING · PHASE2
• Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma — RECRUITING · NA
• Universal CAR-T Cell Therapy for MM — RECRUITING · NA
• Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients — RECRUITING · PHASE1
• A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies — RECRUITING · PHASE1
• Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma — RECRUITING · PHASE1
• All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma — RECRUITING · PHASE2
• A Trial of Selinexor, Ruxolitinib and Methylprednisolone — RECRUITING · PHASE1
• A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma — RECRUITING · PHASE2
• LMY-920 for Treatment of Relapsed or Refractory Myeloma — RECRUITING · PHASE1
• APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma — RECRUITING · PHASE1
• CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies — RECRUITING · PHASE1
• Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study — NOT_YET_RECRUITING
• Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM) — NOT_YET_RECRUITING · PHASE1
• Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma — NOT_YET_RECRUITING · PHASE1
• BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma — WITHDRAWN · PHASE1
• UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma — WITHDRAWN · PHASE1
• Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. — NOT_YET_RECRUITING · PHASE1
• Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma — ACTIVE_NOT_RECRUITING
• Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells — COMPLETED · PHASE1
• A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma — TERMINATED · PHASE1
• Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study — COMPLETED · PHASE4
• Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma — NOT_YET_RECRUITING · PHASE2
• A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors — WITHDRAWN · PHASE1
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies — TERMINATED · PHASE2
• Marizomib Central Nervous System (CNS) — WITHDRAWN · PHASE2
• Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma — OTHER · PHASE1
• Alvocade® (Bortezomib) Safety and Effectiveness Study — COMPLETED
• Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM — NOT_YET_RECRUITING · PHASE2
• Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM — OTHER · PHASE1
• Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma — OTHER · PHASE1
• Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM — OTHER · PHASE1
• Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. — WITHDRAWN · PHASE1
• Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma — OTHER · PHASE2
• A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients — OTHER · PHASE1
• Long-term KRd in Relapsed and/or Refractory Multiple Myeloma — OTHER
• A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment — COMPLETED · PHASE1
• Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma — OTHER · PHASE1
• Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma — COMPLETED · PHASE2

Refine this search